{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:57:48Z","timestamp":1789516668516,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.drudis.2024.104134","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T18:06:42Z","timestamp":1722881202000},"page":"104134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms"],"prefix":"10.1016","volume":"29","author":[{"given":"Hendrikus Bernhard","family":"Bouwman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104134_b0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"issue":"Supplement_1","key":"10.1016\/j.drudis.2024.104134_b0010","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2019-125867","article-title":"Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US","volume":"134","author":"Jalbert","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/j.1460-2075.1994.tb06240.x","article-title":"Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene","volume":"13","author":"Bessler","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2024.104134_b0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.104134_b0025","unstructured":"Charles A Janeway J, Travers P, Walport M, Shlomchik MJ. The complement system and innate immunity. Published online 2001. Accessed September 10, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK27100\/."},{"key":"10.1016\/j.drudis.2024.104134_b0030","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/10428190600555520","article-title":"PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis","volume":"47","author":"Brodsky","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drudis.2024.104134_b0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","article-title":"Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors","volume":"348","author":"Soci\u00e9","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.104134_b0045","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0050","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2024.104134_b0055","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"issue":"Supplement_1","key":"10.1016\/j.drudis.2024.104134_b0060","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1182\/blood-2019-125917","article-title":"Hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: application of a novel classification to identify unmet clinical needs and future clinical goals","volume":"134","author":"Debureaux","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0065","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","article-title":"Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Hillmen","year":"2010","journal-title":"Am J Hematol"},{"issue":"Suppl 4","key":"10.1016\/j.drudis.2024.104134_b0070","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/ndt\/gfu030","article-title":"Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry","volume":"29","author":"W\u00fchl","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2024.104134_b0075","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical hemolytic uremic syndrome: a brief review","volume":"9","author":"Zhang","year":"2017","journal-title":"Hematol Rep"},{"key":"10.1016\/j.drudis.2024.104134_b0085","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0090","doi-asserted-by":"crossref","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.drudis.2024.104134_b0095","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/ndt\/gfq010","article-title":"Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)","volume":"25","author":"Westra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2024.104134_b0100","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0105","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.drudis.2024.104134_b0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00467-010-1690-z","article-title":"Pandemic H1N1 influenza A infection and (atypical) HUS\u2013more than just another trigger?","volume":"26","author":"Allen","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00467-010-1649-0","article-title":"Hemolytic uremic syndrome triggered with a new pandemic virus: influenza A (H1N1)","volume":"26","author":"\u00c7altik","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0120","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/ndt\/gfp166","article-title":"Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases","volume":"24","author":"Kwon","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2024.104134_b0125","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0130","first-page":"1676","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"https:\/\/doi.org\/101056\/NEJMra0902814"},{"key":"10.1016\/j.drudis.2024.104134_b0135","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104134_b0140","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.drudis.2024.104134_b0145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.drudis.2024.104134_b0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1196\/annals.1254.053","article-title":"The epidemiology of myasthenia gravis","volume":"998","author":"Phillips","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.drudis.2024.104134_b0155","first-page":"10","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0160","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0165","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1126\/science.182.4109.293","article-title":"Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors","volume":"182","author":"Fambrough","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.104134_b0175","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0180","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2024.104134_b0185","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2024.104134_b0190","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.104134_b0195","first-page":"13","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","author":"Aguirre","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.drudis.2024.104134_b0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2024.104134_b0205","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0210","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0215","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2024.104134_b0220","first-page":"349","article-title":"Severe worsening of myasthenic symptoms after the eculizumab discontinuation","author":"Uzawa","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.drudis.2024.104134_b0225","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0230","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/174720","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.drudis.2024.104134_b0240","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2024.104134_b0245","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0250","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2024.104134_b0255","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2024.104134_b0260","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0265","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2024.104134_b0270","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11940-005-0010-6","article-title":"Neuromyelitis optica","volume":"7","author":"Wingerchuk","year":"2005","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0275","first-page":"128","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"http:\/\/dx.doi.org\/101177\/1352458506071174"},{"key":"10.1016\/j.drudis.2024.104134_b0280","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2024.104134_b0285","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (devic disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0290","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0295","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2024.104134_b0300","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104134_b0305","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2024.104134_b0310","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0315","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2024.104134_b0320","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.drudis.2024.104134_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Translat Res"},{"key":"10.1016\/j.drudis.2024.104134_b0330","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study","volume":"11","author":"Giudice","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2024.104134_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study","volume":"28","author":"Annane","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drudis.2024.104134_b0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261113","article-title":"Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: retrospective cohort study","volume":"16","author":"Ruggenenti","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.104134_b0345","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.104134_b0350","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-017-0802-4","article-title":"Treating C3 glomerulopathy with eculizumab","volume":"19","author":"Welte","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-023-03058-9","article-title":"Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study","volume":"24","author":"Welte","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0360","unstructured":"Evans MJ, et al. C5-specific antibodies for the treatment of inflammatory diseases. Published online June 7, 1995."},{"key":"10.1016\/j.drudis.2024.104134_b0365","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0370","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104134_b0375","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V126.23.1209.1209","article-title":"C5 Polymorphism in a Dutch patient with paroxysmal nocturnal hemoglobinuria (PNH) and no Asian ancestry, resistant to eculizumab, but in vitro sensitive to coversin","volume":"126","author":"Langemeijer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0380","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169135","article-title":"Eculizumab treatment alters the proteometabolome beyond the inhibition of complement","volume":"8","author":"Nelke","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2024.104134_b0385","unstructured":"European Medicines Agency (EMA). Assessment Report: Eculizumab; 2013. Accessed September 21, 2023. www.ema.europa.eu."},{"key":"10.1016\/j.drudis.2024.104134_b0390","series-title":"Eculizumab: summary of product characteristics","author":"European Medicines Agency (EMA)","year":"2023"},{"key":"10.1016\/j.drudis.2024.104134_b0395","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/ndt\/gfac056","article-title":"Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective","volume":"38","author":"Ter Avest","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2024.104134_b0400","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2024.104134_b0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.104134_b0410","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0415","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0420","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"Mabs"},{"key":"10.1016\/j.drudis.2024.104134_b0425","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2024.104134_b0430","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2024.104134_b0435","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-013-1404-y","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial","volume":"98","author":"Kanakura","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.drudis.2024.104134_b0440","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/DHPS.S257009","article-title":"Risk analysis of eculizumab-related meningococcal disease in Japan using the Japanese adverse drug event report database","volume":"12","author":"Matsumura","year":"2020","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.drudis.2024.104134_b0445","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"Morbidity Mortality Week Rep"},{"key":"10.1016\/j.drudis.2024.104134_b0450","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3201\/eid2408.180228","article-title":"Fatal nongroupable neisseria meningitidis disease in vaccinated patient receiving eculizumab","volume":"24","author":"Nolfi-Donegan","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.drudis.2024.104134_b0455","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0460","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/ciy958","article-title":"Disseminated gonococcal infections in patients receiving eculizumab: a case series","volume":"69","author":"Crew","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.drudis.2024.104134_b0465","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/IJGM.S255298","article-title":"Disseminated gonococcal infection associated with eculizumab therapy for paroxysmal nocturnal hemoglobinuria: a case report and literature review","volume":"13","author":"Saito","year":"2020","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.drudis.2024.104134_b0470","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jinf.2018.10.015","article-title":"Unusual neisseria species as a cause of infection in patients taking eculizumab","volume":"78","author":"Crew","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.drudis.2024.104134_b0475","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/j.cell.2023.04.031","article-title":"C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection","volume":"186","author":"Desai","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.104134_b0480","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","article-title":"Eculizumab hepatotoxicity in pediatric aHUS","volume":"30","author":"Hayes","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0485","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2024.104134_b0490","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.nefro.2017.10.001","article-title":"Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome","volume":"38","author":"Oruc","year":"2018","journal-title":"Nefrologia"},{"key":"10.1016\/j.drudis.2024.104134_b0495","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1567-5769(00)00038-2","article-title":"Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells","volume":"1","author":"Schieferdecker","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2024.104134_b0500","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.4049\/jimmunol.166.4.2479","article-title":"A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration","volume":"166","author":"Mastellos","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0505","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.2012.09145.x","article-title":"From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging","volume":"158","author":"Risitano","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2024.104134_b0510","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2018-99-114654","article-title":"Iron overload in patients with paroxysmal nocturnal hemoglobinuria","volume":"132","author":"Lukina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0515","doi-asserted-by":"crossref","first-page":"E235","DOI":"10.1002\/ajh.26187","article-title":"Iron overload after complement inhibitor treatment of paroxysmal nocturnal hemoglobinuria","volume":"96","author":"Waheed","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.drudis.2024.104134_b0520","doi-asserted-by":"crossref","unstructured":"Schaap CC, et al. Effect of eculizumab on iron metabolism in transfusion-independent patients with paroxysmal nocturnal hemoglobinuria. Published online 2023. https:\/\/doi.org\/10.1097\/HS9.0000000000000878.","DOI":"10.1097\/HS9.0000000000000878"},{"key":"10.1016\/j.drudis.2024.104134_b0525","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1423-0410.2011.01530.x","article-title":"Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test","volume":"102","author":"H\u00f6chsmann","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.drudis.2024.104134_b0530","doi-asserted-by":"crossref","first-page":"21","DOI":"10.17161\/rrnmf.v4i2.18489","article-title":"Poor response to eculizumab in Caucasian patients with treatment refractory generalized myasthenia gravis: a case series","volume":"4","author":"Katyal","year":"2023","journal-title":"RRNMF Neuromusc J"},{"key":"10.1016\/j.drudis.2024.104134_b0535","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.2021011388","article-title":"Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab","volume":"138","author":"Kulasekararaj","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0540","first-page":"13","article-title":"Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients","author":"Mosch","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0545","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2024.104134_b0550","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ajh.24280","article-title":"Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria","volume":"91","author":"Hillmen","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.drudis.2024.104134_b0555","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The Complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104134_b0560","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0565","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/JBM.S361863","article-title":"Low rate of clinically evident extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with a complement C5 inhibitor: Results from a large, multicenter, US real-world study","volume":"13","author":"Shammo","year":"2022","journal-title":"J Blood Med"},{"key":"10.1016\/j.drudis.2024.104134_b0570","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0575","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2015-02-625871","article-title":"Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria","volume":"126","author":"Lin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0580","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2024.104134_b0585","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/bloodadvances.2016002832","article-title":"Use of the complement inhibitor Coversin to treat HSCT-associated TMA","volume":"1","author":"Goodship","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2024.104134_b0590","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0595","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2005-06-2373","article-title":"Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease","volume":"107","author":"Kato","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0600","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","article-title":"Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial","volume":"93","author":"Kanakura","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.drudis.2024.104134_b0605","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.16305","article-title":"Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)","volume":"188","author":"Mahon","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2024.104134_b0610","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0615","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0620","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-99-111230","article-title":"Current status and optimal management of eculizumab poor-responders due to C5 polymorphisms","volume":"132","author":"Ueda","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104134_b0625","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s12185-020-02934-6","article-title":"Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients","volume":"112","author":"Ishiyama","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.drudis.2024.104134_b0630","first-page":"50","article-title":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: a subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","author":"Kim","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.drudis.2024.104134_b0635","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1167\/iovs.15-16645","article-title":"Complement C5 gene confers risk for acute anterior uveitis","volume":"56","author":"Xu","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2024.104134_b0640","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.2147\/JIR.S340446","article-title":"Investigation of association of complement 5 genetic polymorphisms with sepsis and sepsis-induced inflammatory responses","volume":"14","author":"Chen","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.drudis.2024.104134_b0645","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.4049\/jimmunol.174.7.4172","article-title":"Linking C5 deficiency to an exonic splicing enhancer mutation","volume":"174","author":"Pfarr","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0650","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/cei.12967","article-title":"Complement factor 5 (C5) p.A252T mutation is prevalent in, but not restricted to, sub-Saharan Africa: implications for the susceptibility to meningococcal disease","volume":"189","author":"Franco-Jarava","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0655","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.4049\/jimmunol.154.10.5464","article-title":"Inherited human complement C5 deficiency: nonsense mutations in exons 1 (Gln1 to stop) and 36 (Arg1458 to stop) and compound heterozygosity in three African-American families","volume":"154","author":"Wang","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2024.104134_b0660","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40265-021-01481-6","article-title":"Ravulizumab: a review in atypical haemolytic uraemic syndrome","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2024.104134_b0665","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2024.104134_b0670","article-title":"Korean Variant Archive (KOVA): a reference database of genetic variations in the Korean population","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104134_b0675","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/aje\/kwr160","article-title":"The next PAGE in understanding complex traits: design for the analysis of population architecture using genetics and epidemiology (PAGE) study","volume":"174","author":"Matise","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.drudis.2024.104134_b0680","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz7835","article-title":"Korean Genome Project: 1094 Korean personal genomes with clinical information","volume":"6","author":"Jeon","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2024.104134_b0685","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/database\/baz146","article-title":"KRGDB: the large-scale variant database of 1722 Koreans based on whole genome sequencing","volume":"2020","author":"Jung","year":"2020","journal-title":"Database"},{"key":"10.1016\/j.drudis.2024.104134_b0690","article-title":"A genome-wide mutational constraint map quantified from variation in 76,156 human genomes","author":"Chen","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2024.104134_b0695","unstructured":"Phan, L. et al. ALFA: Allele Frequency Aggregator. Published online March 10, 2020. www.ncbi.nlm.nih.gov\/snp\/docs\/gsr\/alfa\/."},{"key":"10.1016\/j.drudis.2024.104134_b0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41439-019-0059-5","article-title":"3.5KJPNv2: an allele frequency panel of 3552 Japanese individuals including the X chromosome","volume":"6","author":"Tadaka","year":"2019","journal-title":"Hum Genome Variat"},{"key":"10.1016\/j.drudis.2024.104134_b0705","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104134_b0710","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2012.09166.x","article-title":"Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function","volume":"158","author":"Hill","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2024.104134_b0715","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","article-title":"Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions","volume":"28","author":"Mealy","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.drudis.2024.104134_b0720","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40273-019-00862-w","article-title":"Economic impact of early-in-hospital diagnosis and initiation of eculizumab in atypical haemolytic uraemic syndrome","volume":"38","author":"Ryan","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.drudis.2024.104134_b0725","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0055","article-title":"The cost\u2013effectiveness of pegcetacoplan in complement treatment-na\u00efve adults with paroxysmal nocturnal hemoglobinuria in the USA","author":"Fishman","year":"2023","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.drudis.2024.104134_b0730","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389201023378175","article-title":"Immune responses to therapeutic proteins in humans \u2013 clinical significance, assessment and prediction","volume":"3","author":"Koren","year":"2002","journal-title":"Curr Pharm Biotechnol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T21:33:13Z","timestamp":1725053593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624002599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":146,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1359644624002599"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104134","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104134"}}